+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

Annual CIBER-BBN and NANBIOSIS Conference 2021 – SAVE THE DATE

On 15-16 noviembre 2021 will be hold the annual Conference of CIBER-BBN and NANBIOSIS

CIBER-BBN´s Annual Conference is the most awaited yearly event for our research community to gather and discuss over past year´s achievements as well as to be updated about emerging key technologies. Under this light, this year´s edition includes presentations of internal collaborative projects, three plenary talks given by acknowledged experts in the fields of Biosignal Analysis, Hybrid Nanomaterials and Drug Delivery and a session dedicated to COVID-19 and the most recent advances in the fight against it as for detection, prevention and therapy.

Due to this year´s exceptional circumstances, XIV CIBER-BBN Conference will be held on-line.

Access to broadcasted talks and subsequent debate is free following registration to the event at https://jornadasanuales.ciber-bbn.es

Program and registration

Read More

Characterization of encapsulated porcine cardiosphere-derived cells for cardiac regeneration.

Researchers of NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and UPV/EHU and NANBIOSIS U14 Cell Therapy unit and U24 Medical imaging unit at CCMIJU have participated in a research that proposes the use of encapsulated cardiosphere-derived cells (CDC), obtained from heart tissue, as regenerative cell therapy.

The encapsulation of the cells has been carried out in NANBIOSIS Unit 10, as well as the characterization of the cells (both encapsulated and unencapsulated) for their application in regenerative medicine (cardiac regeneration); and unit 14 of NANBIOSIS has obtained the cell model used for the study “ – Explains Kaoutar Ziani Akrirout, research scientists of CIBER-BBN and NANBIOSIS Unit 10.

These cells are multipotent stem cells, which secrete growth factors capable of promoting revascularization and healing of infarcted tissue. However, the use of this therapy faces a great challenge, which is the survival and retention of these cells after their implantation in the infarcted area, since the heart is a tissue that is constantly contracting and expanding, which leads to the loss of these cells, as they are carried along by the bloodstream.

To solve the low retention of cells, members of the NanoBioCel research team, from the CIBER-BBN and attached to the Bioaraba Health Research Institute (IIS Bioaraba), in collaboration with researchers from the IIS Aragón and the CIBERCV, propose the encapsulation of the CDC of porcine origin within a three-dimensional alginate-poly-L-lysine-alginate matrix as a therapy for cardiac regeneration, since, thanks to this, the encapsulated cells will be able to remain adhered to the tissue for longer, giving them time to exercise their function. The final objective will be to verify its efficacy in swine infarction models.

The team has verified that the phenotypic characteristics, the gene expression profile, the ability to differentiate to other cell lines and the release of growth factors from these cells are not altered by the encapsulation process, essential aspects given that their preservation it is essential for cardiac regeneration. In addition, this procedure keeps them viable for a month, which would favor the possible regeneration of the tissue.

On the other hand, that a sustained release of growth factors is maintained in these cells suggests that the implantation of encapsulated CDCs will promote the formation of new blood vessels and, consequently, the regeneration of infarcted cardiac tissue.

The researchers suggest that encapsulated CDCs could be a highly interesting therapeutic alternative in the field of cardiac regenerative medicine.

Article of reference

Ziani K, Espona-Noguera A, Crisóstomo V, Casado JG, Sanchez-Margallo FM, Saenz-Del-Burgo L, Ciriza J, Pedraz JL. Characterization of encapsulated porcine cardiosphere-derived cells embedded in 3D alginate matrices. Int J Pharm. 2021 Apr 15;599:120454.[DOI

Read More

Inkjet printing technology is driving innovation of sensors for point-of-care devices

Miguel Zea, researcher at GAB Group –  Nanbiosis U8 Micro– Nano Technology Unit  will defend hir PhD thesis on Friday 23 of July, at 11 am, at the Graus Room of the Faculty of Sciences and Biosciences of the UAB about “Inkjet printing technology is driving the innovation of sensors for point-of-care devices”

Thesis directors: Gemma Gabriel and Eloi Ramon

Further information and registration for the event, onñine, here


The ‘Inkjet printing’ technology is called to be the next generation of flexible electronics capable of performing functions that were only accessible with state-of-the-art microfabrication technologies. This is due, in part, to the versatility of digital, non-contact patterning techniques but also to the substantial investment in research and development for inkjet printing of functional materials in recent years. Inkjet printing is an additive manufacturing technology based on the contact-less deposition of micro-droplets of a functional material with micrometer precision on the desired substrate area, through a digital design. Moreover, inkjet printing is capable of modifying the printing pattern in real time. Consequently, design changes can be introduced without any additional costs, allowing to create personalized designs with unique features. Nowadays, industrial inkjet printing has reached high standards of flexible, robust, and reliable performances.

The consensus is that inkjet printing will facilitate the production of flexible electronics in a cost-effective, on circular-economy, and reducing waste manner, enabling the development of currently unavailable wearable and disposable devices. This is the point at which Point-of-Care testing devices (PoCT) enter in the equation due to their importance in medical trails. These devices are defined as medical diagnostic testing at or near the patient. PoCT devices rely on a fast and accurate measurement based on sensors that provide the physician with a set of important data to make a diagnosis. However, major limitations of state-of-the-art PoCT devices include cost, disposability, biodegradability, and reliability. Inkjet printing technology offers solutions to address these problems where its great promises are low-cost, non-contact, rapid prototyping, material varieties, and wide range of substrates. Moreover, in the last 15 years, this technology has already shown its potential in the fabrication of reliable and quantitative sensors which form the essential components of PoCT devices. However, our understanding of the technology and its capabilities are still in a promising or potential stage, and further expertise needs to be acquired to facilitate the development of complete fully printed PoCT devices.

Identifying these problems and possible solutions, this thesis focuses on showing the potential of inkjet printing to develop sensors on flexible plastic substrates and porous paper, challenging technology to its current limit. The first part addresses the formulation, printing, and characterization of new functional inks that allow us to obtain new conductive inks to be used in the area of sensing analytes of interest. On flexible plastic, two potentiometric pH sensors have been developed. The first shows the importance of the intrinsic roughness property of a new platinum ink based on nanoparticles to provide mechanical stability to iridium oxide, a pH-sensitive material, grown electrochemically on it. For this purpose, a pH sensor was developed using the new Pt ink and the stability over a year of this iridium oxide layer was studied, which showed a clear improvement in its performance. The second pH sensor goes one step further and is, to date, the first pH sensor entirely fabricated by inkjet printing. To meet this objective, a new polymeric ink was formulated composed of a mixture of polypyrrole and pH-sensitive polyaniline. This ink was printed on a previously printed gold microelectrode and, to finally obtain a fully printed pH sensor, the fabrication was completed with a printed silver/silver chloride pseudo-reference electrode. The second part addresses the challenge of printing a sensor on a more eco-sustainable substrate such as paper, an important factor for disposable PoCs. On any paper substrate, the difficulty in printing is greater due to the porosity, delicacy, and hydrophilicity of this material. In a first work, the challenge of printing conductive functional inks such as gold or silver, and dielectric inks such as SU8 on the substrate in an efficient and easy-to-reproduce way to obtain an electrochemical sensor is addressed. The printing of a new hydrophobic ink that allows to selectively block the area of the paper where the printing of the conductive inks that make up the electrochemical sensor will be required is proposed and studied. Finally, in a second work, a cortisol immunosensor was implemented on these sensors printed on a paper substrate and its response was characterized and compared with other reported sensors, demonstrating the good performance of this technology in the detection of biological target molecules in biological samples.

Read More

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021.

The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors

José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting with the expertise of José Amable Bernabé and the Ex vivo and in vivo studies with dendrimers for MRI of NANBIOSIS U25 with the expertise of Ana Paula Candiota.

ICMAB FIPs are possible thanks to the financial support from the Spanish Ministry Science and Innovation, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (CEX2019-000917-S).

Read More

Study of new liposomes for the delivery of enzymes through biological membranes

Judit Tomsen, researcher at Nanomol Group – NANBIOSIS U6 (ICMAB-CSIC and CIBER-BBN)  will defend her PhD thesis on Thursday, 15 July 2021, at 11 am in an hybrid session, from the ICMAB Seminar Room “Carles Miravitlles”. 

Further information and Registration to attend the PhD Thesis defense via Zoom  at ICMAB-website.


Nora Ventosa (Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit and leader of Nanomol Group of CIBER-BBN- ICMAB-CSIC

Elisabet González, Nanomol Group of CIBER-BBN – ICMAB-CSIC

Abstract: Liposomes are lipid-based nanovesicles widely explored as nanocarriers for the transport of biomolecules or drugs of interest to the place of action, and for the development of new nanomedicines. This Thesis is devoted to the study of liposomal systems functionalized with targeting-ligands, with the final goal to be used as nanocarriers of therapeutically active enzymes. The new liposomal formulations have been specifically investigated and developed for the effective transportation of α-galactosidase A enzyme through cellular and blood-brain membranes, and for the achievement of a new liposomal intravenous pharmaceutical product candidate (nanoGLA) for the treatment of Fabry disease. The achieved results support the strong potential of targeted liposomal systems for drug delivery application. The successful development and optimization of the nanoGLA product for improving the current enzymatic replacement therapy in Fabry disease especially contributes as an example of translational and interdisciplinary research.

Read More

New NANBIOSIS’ focus on Cutting-Edge Biomedical Solutions

We are delighted to announce the publication of our new corporate brochure which reflects NANBIOSIS’s main core competences. This fresh looking promotion material has been intentionally designed to emphasize our experience of join expertise and capabilities solving problems in biomedical research, focussing on quality, adaptability and excellence commitment.

The NANBIOSIS’ Cutting-Edge biomedical solutions  have been updated to offer a wider range of Integrated solutions to advanced challenges faced by biomedical researchers in the fields of tissue engineering, regenerative medicine, diagnostic and medical devices.

The Cutting-Edge biomedical solutions offered by the ICTS NANBIOSIS have been organised drilling down on our key areas:

  • Customized biomolecules production & Validation
  • Customized nanomedicines production & Preclinical Validation
  • Customized biomaterials production & Preclinical Validation
  • Diagnostic Devices production & Validation

Downloadable PDF of the brochure is here available

Read More

Jaume Veciana awarded by the Catalan Society of Chemistry with the Prize to the Scientific Excellence

Jaume Veciana Miró, Director of NANBIOSIS, has been awarded by the Catalan Society of Chemistry in its 2021 edition of Awards in research, education and dissemination with the Prize to the Scientific Excellence for his scientific career.

Read More

Online Course in Basic Procedures and Introduction to Mesenchymal Stem Cell Culture

From 30 August 2021 to 29 September 2021 Jesus Usón Minimally Invasive Surgery Centre (JUMISC) has organized an on line course on Procedures and Introduction to Mesenchymal Stem Cell Culture. The course is directected by Francisco Miguel Sánchez Margallo and run by researchers of NANBIOSIS U14 Cell Therapy Unit at JUMISC

Stem cells are cells capable of differentiating into a wide variety of cell types and can be isolated from different tissues. They have regenerative and anti-inflammatory properties thanks to the secretion of paracrine factors. Currently, these cells are being widely used in clinical trials for the treatment of different diseases such as Crohn’s disease, multiple sclerosis, diabetes, rheumatoid arthritis or myocardial infarction.

The objectives of this course is to teach the student to work in cell culture rooms, perform stem cell isolations, as well as the maintenance, expansion and conservation of these cell lines. You will also learn to characterize and differentiate these cell lines.

Once the course is finished, the student will be able to know the necessary equipment in a cell culture laboratory, the risks derived from working in these laboratories and the basic rules that must be taken into account to work in cell culture rooms. The student will also learn to prepare culture media, isolate stem cells from different tissues and everything necessary for the maintenance, expansion and conservation of cell lines. In addition, she will be able to acquire knowledge related to the differentiation protocols to different lineages: adipogenic, osteogenic and chondrogenic differentiation.


Francisco Miguel Sánchez Margallo
Scientific Director of CCMIJU / Deputy Scientific Director of NANBIOSIS

Esther Lopez Nieto
Researcher at the Cell Therapy Unit of NANBIOSIS
of the JUMISC


Dr Javier García Casado.
Scientific Director of NANBIOSIS U14 Cell Therapy Unit
Postdoctoral researcher at the Cell Therapy Unit of the JUMISC

Dr Esher López.
Researcher at the Cell Therapy Unit of the JUMISC / NANBIOSIS

Federica Marinaro.
Researcher at the Cell Therapy Unit of the JUMISC / NANBIOSIS

Mª de los Angeles de Pedro
Researcher at the Cell Therapy Unit of the JUMISC / NANBIOSIS

Maria Pulido
Researcher at the Cell Therapy Unit of the JUMISC / NANBIOSIS

Veronica Alvarez.
JUMISC Superior Laboratory Technician

Information and enrollment here

Read More

New project ExofluidTT for the production of nanovesicles using microfluidics applicable on Biomedicine

Víctor Sebastián Cabeza, researcher of NANBIOSIS U9 Synthesis of Nanoparticles of CIBER-BBN and the Institute of Nanoscience and Materials of Aragón, INMA, has obtained a research grant in the XX National Contest of the Ramón Areces Foundation in the category of Life and Matter Sciences with a funding of € 112,000 for the development in 3 years of nanovesicles using microfluidic technology.

As explained by Victor Sebastian “the characterization of the nanovesicles will be carried with the equiment and expertise of NANBIOSIS Unit 9

The project entitled “Engineering of extracellular vesicles-exosomes using microfluidic technology for its application in biomedicine: ExoFluidTT” aims to develop new procedures to improve the selectivity and efficiency of therapeutic treatments, such as, for example, cancer. The nanocarriers considered in ExoFluidTT are called exosomes and are nano-sized extracellular vesicles, produced by the patient’s own cells and whose structure and composition is so complex that their production by synthetic procedures is not possible. The application of these vesicles is creating a revolution in cellular treatments, since they allow to face the problems in which artificial nanocarriers fail. However, its clinical use is complex, due to the difficulty of its production, isolation and reconfiguration for the treatment of diseases.

The ExoFLuidTT project aims to design an innovative platform based on the use of exosomes for its application in targeted therapies. The basis of this innovative platform is based on the use of microfluidic technology to obtain the exosomes of the patient’s cells. These exosomes would be isolated for their reconfiguration aimed at obtaining nanocarriers that allow the administration of drugs in a targeted manner. This microfluidic technology consists of a complex system of pipes and micrometric-scale reactors (similar to the dimensions of a human hair) that mimic the highly efficient network of blood capillaries that the human body has, so that, in an efficient way, they can be manipulate volumes of fluid on the scale of picoliters (one millionth of a drop).

This project is based on the previous experience of Víctor Sebastián Cabeza in the development of microfluidic technology for multiple uses in Catalysis, Materials Engineering and Nanobiomedicine, as well as the experience of his work team, ExoFLuidTT, in the use of exosomes as therapeutic nanocarriers. This team has recently published a study where they were able to successfully develop exosomes modified with palladium nanosheets for the selective activation of prodrugs in-vitro and to treat tumor cells selectively. The results of this work were published in the prestigious journals Nature Catalysis and Nature Protocols and open a therapeutic pathway that can have a great social impact.

The project work team, led by Víctor Sebastián, is made up of CIBER-BBN researchers Manuel Arruebo and Jesús Santamaría, all of them professors from the Department of Chemical Engineering and Environmental Technologies at UNIZAR, and researchers from INMA and IISAragón . Researchers Silvia Irusta (INMA / CiberBBN / IIS Aragón) and Pilar Martín Duque (ARAID / IACS / IISAragón) collaborate with this team.

Read More

Ibane Abasolo new Scientific Director of unit 20 of NANBIOSIS

Ibane Abasolo, the Scientific Coordinator of NANBIOSIS U20 of the CIBER-BBN at the Vall d’Hebron Research Institute (VHIR), has been appointed new Scientific Director, replacing Simó Schwartz, who has recently assumed the Directorate of the Blood and Tissue Bank of Catalonia. With her, there are 11 women who are Scientific Directors of NANBIOSIS units (46%), with the incorporation of Nora Ventosa and Rosa Villa during the past year 2020. Ibane Abasolo has also been appointed IP of the CIBER group that coordinates unit 20 of NANBIOSIS. The female replacement in the leadership of the CIBER groups is one of the priorities of the consortium and all the recent IP substitutions of the CIBER-BBN have been appointed researchers as group leaders.

Ibane Abasolo obtained degrees in Biochemistry and Biology from the University of Navarra in 1997 and 1998, respectively. During her doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), she studied the role of a peptide hormone, adrenomedullin, in the prostate cancer. Dr. Abasolo continued her postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where she focused on the study of key factors on the progression of pancreatic cancer and the development of the cerebellum. During this time, she gained extensive experience in experimental mouse models, including all steps from the generation of new transgenic models, to the molecular and cellular characterization of existing ones. Later, Dr. Abasolo moved to the High Technology Institute (PRBB, Barcelona), where she was trained in molecular imaging techniques such as microPET, SPECT and CT.

Dr. Abasolo has been part of the CIBER-BBN since 2007, when she joined the group led by Dr. Schwartz at the Vall d’Hebron Hospital, where she launched the Functional Validation and Preclinical Research Area (FVPR) of the CIBBIM -Nanomedicine as a technological platform from which industry or academic groups can advance in the preclinical development of its compounds. In fact, FVPR is part of Unit 20 and the Singular Scientific Technical Infrastructure (ICTS) Nanbiosis and is certified with ISO9001: 2015.

As a researcher, Dr. Abasolo currently collaborates in 4 European projects (NoCanTher, EvoNano, Safe-Med-Tech and Mimic-Key) and leads many other national projects, focused on improving the treatment of lysosomal storage disorders (PI18 / 00871 from ISCIII and ExoProd funded by FIPSE) or in the study of the role of tumor stem cells in cancer progression (NanoDireCT, RETOS-Collaboration project). At CIBER-BBN, Dr. Abasolo directly coordinates 3 intramural projects and a recently awarded valorization project (ADVERT).

Read More